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ABSTRACT The diagnosis of tuberculosis (TB) in HIV-infected patients is challeng-
ing. Both a urinary lipoarabinomannan (LAM) test (Alere TB LAM) and GeneXpert-
MTB/RIF (Xpert) are useful for the diagnosis of TB. However, how to optimally inte-
grate Xpert and LAM tests into clinical practice algorithms remain unclear. We
performed a post hoc analysis of 561 HIV-infected sputum-expectorating patients
(median CD4 count of 130 cells/ml) from a previously published randomized con-
trolled trial evaluating the LAM test in hospitalized HIV-infected patients with sus-
pected TB. We evaluated 5 different diagnostic strategies using sputum culture as a
reference standard (Xpert alone, LAM alone, sequential Xpert followed by LAM and
vice versa [LAM in Xpert-negative patients and Xpert in LAM-negative patients], and
both tests concurrently [LAM  Xpert]). A cost-consequence analysis was performed.
Strategy-specific sensitivity and specificity, using culture as a reference, were similar
with the Xpert-only and sequential and concurrent strategies. However, when any
positive TB-specific test was used as a reference, the incremental yield of LAM over
Xpert was 29.6% (45/152) and that of Xpert over LAM was 75% (84/11). The incre-
mental yield of LAM increased with decreasing CD4 count. The costs per TB case di-
agnosed were similar for the sequential and concurrent strategies ($1,617 to $1,626).
In sputum-expectorating hospitalized patients with advanced HIV and access to both
tests, concurrent testing with Xpert and LAM may be the best strategy for diagnos-
ing TB. These data inform clinical practice in settings where TB and HIV are endemic.
KEYWORDS tuberculosis, HIV, lipoarabinomannan, GeneXpert MTB/RIF,
Mycobacterium tuberculosis, human immunodeficiency virus
In sub-Saharan Africa, the co-epidemics of tuberculosis (TB) and HIV are out of control(1). Approximately 70% of all incident TB cases in HIV-infected persons occur in Africa,
and 17% of the total TB deaths are associated with HIV (2). The high case fatality rate
from HIV-TB coinfection is related to disseminated and extrapulmonary forms of TB
(EPTB) in patients with advanced immunosuppression (3), where the diagnosis is often
missed or delayed. Indeed, postmortem studies demonstrate that TB is the cause of
death in 40 to 60% of hospitalized HIV patients (4–6), with the diagnosis having been
missed in over 45% of patients (4–6).
However, two tests have recently been shown to be effective for TB diagnosis in the
setting of advanced HIV coinfection. The GeneXpert MTB/RIF test (Xpert) is an auto-
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mated, sputum-based, real-time PCR assay that permits rapid identification of Myco-
bacterium tuberculosis and determination of rifampicin resistance (7). However, while
access to Xpert testing has been proven to reduce time to treatment initiation (8, 9), it
performs suboptimally in HIV-infected patients, who often have sputum smear-
negative disease (10). The Alere Determine TB LAM Ag lateral flow strip test is a bedside
urine-based test that identifies lipoarabinomannan (LAM), a glycolipid component of
the mycobacterial cell wall, and provides a result in 25 min (11). It is World Health
Organization (WHO) approved for use in HIV-infected patients with advanced immu-
nosuppression (12, 13) and has been shown to reduce mortality in hospitalized
HIV-positive patients when used to guide TB treatment initiation (14, 15). The urine LAM
test has obvious advantages, as it is a point-of-care test facilitating rapid treatment
initiation, the sample is easy to collect, and sample collection does not entail the same
infection control concerns as that of sputum.
Current WHO guidelines recommend urine LAM testing in all HIV-infected hospital-
ized patients with advanced immunosuppression (CD4 count of 100 cells/ml or stage
3/4 disease) or who are seriously ill, irrespective of signs or symptoms of TB (16). Thus,
the LAM test should be used as a screening test in this population. In hospitalized
HIV-infected persons with a CD4 count of 100 cells/ml, LAM testing is also indicated
in those with signs and symptoms of TB.
However, the guidelines are unclear on how newer tests like Xpert and the LAM test
should be integrated into clinical practice in high-HIV-prevalence settings. This is a
critical unanswered question in settings where TB and HIV are endemic and where,
often, either only one or both tests are available. Thus, it is unclear whether, in
individual test-specific settings, performing testing sequentially or concurrently may be
more useful; the cost implications thereof remain unstudied. To address this question,
we evaluated the test performance and cost consequence (per TB case diagnosed) of
5 testing strategies (individual [Xpert or urine LAM test alone], sequential [Xpert in
LAM-negative patients or urine LAM test in Xpert-negative patients], or concurrent
testing) in a large cohort of sputum-expectorating hospitalized HIV-infected patients
that formed part of a larger parent study, the results of which are reported elsewhere
(14).
MATERIALS AND METHODS
Study design, conduct, and oversight. This study represents a post hoc subgroup analysis of data
from a pragmatic, randomized, parallel-arm, multicenter study with stratified randomization by country.
The primary analysis has already been reported (14). Prior to patient recruitment into the parent study,
the study was approved by the appropriate national regulatory authorities, by the University of Cape
Town Human Research Ethics Committee (HREC 007/2012), and by the ethics committee at each site. All
patients provided informed consent in their first language prior to enrollment into the parent study. This
trial was registered with Clinicaltrials.gov, number NCT01770730 (https://clinicaltrials.gov/ct2/show/
NCT01770730).
Study patients, enrollment criteria, and randomization. Patients admitted to 10 urban or peri-
urban hospitals in South Africa, Tanzania, Zambia, and Zimbabwe were screened for study inclusion. A
detailed description of hospital care, HIV and TB prevalence, routine clinical care, and the diagnostics
infrastructure at each hospital was reported previously (14). The inclusion criteria included (i) HIV
infection; (ii) at least one of the following symptoms: current fever or cough, drenching night sweats, or
self-reported loss of weight; (iii) illness severe enough to necessitate hospitalization; (iv) age of 18 years;
(v) granting of informed consent. The exclusion criteria included (i) receipt of any anti-TB medication in
the 60 days prior to testing and (ii) inability to provide at least 30 ml urine. Eligible patients were
randomized to receive standard available TB diagnostics at each center or standard TB diagnostics plus
adjunctive LAM, using centralized computer-generated allocation lists, stratified by country. The patients
and the study team were not blinded to both allocation and test results.
Procedures and standard clinical management. In addition to a urine specimen, patients were
asked to expectorate a minimum of two sputum samples for routine TB diagnosis. For patients unable
to self-expectorate, sputum induction was employed. Clinical assessment by the attending physicians
and chest X-ray facilities were available in most cases; however, additional radiology and nonsputum
sampling were differentially available in study hospitals, and requesting these investigations was at the
discretion of the attending clinical team. Xpert was performed on 1 ml of sputum, according to
manufacturer’s instructions (Cepheid, Inc., USA), at all study sites. The urine LAM test was performed at
the bedside, according to manufacturer’s instructions (Alere, USA). A grade 2 cutoff point or higher was
deemed a positive urine LAM result. The attending clinical team made all decisions regarding patient
therapy and initiation of anti-TB treatment and the timing thereof, including acting upon the LAM test
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results. The WHO guidelines for the treatment of smear-negative tuberculosis were routinely used at
study hospitals.
Patient selection for post hoc analysis. For this analysis, only patients randomized to the LAM test
group and for whom Xpert and sputum culture results were available were included (561 patients of the
1,257 patients randomized to the LAM test group) (Fig. 1).
Outcomes and statistical analysis. The goal of this analysis was to assess the utility of single or
sequential TB testing strategies incorporating urine LAM and/or Xpert in HIV-infected patients admitted
for suspected TB. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value
(NPV) were calculated for 5 different strategies using sputum culture positivity as a reference standard:
(i) performing Xpert alone; (ii) performing the urine LAM test alone; (iii) performing Xpert only in patients
with an initial negative LAM result, (iv) performing LAM testing only in patients with an initial negative
Xpert result, and (v) performing Xpert and LAM concurrently (LAMXpert).
In addition, the incremental yield of LAM and Xpert tests in the sequential testing strategies (Xpert
in LAM-negative patients and LAM in Xpert-negative patients) was determined using either sputum
culture positivity or any positive TB test (LAM, Xpert, and/or sputum culture) as a reference standard. An
a priori subgroup analysis was performed on those with CD4 counts of 200 and 50 cells/mm3, as the
diagnostic performance of urine LAM improves with lower CD4 counts (17). All analyses were performed
using Stata V13 (StataCorp). Exact binomial 95% confidence intervals were calculated for proportions,
and differences in proportions were calculated (with 95% confidence intervals using a normal approx-
imation) for comparisons between diagnostic approaches.
Economic evaluation (cost analysis). A cost-consequence analysis was performed from the South
African health care provider perspective to evaluate the different diagnostic strategies 1 to 5 mentioned
above. Costs were expressed in 2018 U.S. dollars at an exchange rate of 13.20 South African rands to 1
U.S. dollar (http://wdi.worldbank.org/table/4.16). Costs were subsequently inflated to the year of analysis
where appropriate using the World Bank Consumer Price Index for South Africa (https://data.worldbank
.org/indicator/FP.CPI.TOTL?locationsZA). The unit cost of Xpert was obtained from the National Health
Laboratory Service (NHLS) and represents the actual cost incurred by the South African National TB
Program. Such estimates have been used in other health economic studies (18–20). The unit cost of the
urine LAM test was calculated using an ingredients approach and included the cost of the assay
(provided by Alere), other consumables, and staff. The cost of anti-TB treatment for 6 months was
obtained from the WHO South African tuberculosis finance profile (21). No discount rate was applied due
to the short time frame of the analysis. Model probabilities were calculated based on test sensitivities and
specificities reported in Table 2. Outcomes were normalized to 1,000 patients screened per strategy. The
FIG 1 Flow diagram demonstrating patient selection and distribution of TB-positive results (LAM, lipoarabinomannan testing; Xpert, GeneXpert MTB/RIF). &,
Excluded patients had similar demographic characteristics and approximately 27% were sputum scarce. #, LAM and/or Xpert and/or Bactec MGIT 960 TB
culture-positive.
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cost-effectiveness of each strategy was reported as the cost per culture-positive case diagnosed and
started on treatment (per 1,000 patients screened). Other effectiveness measures were also considered
(see the supplemental text). A univariate analysis was performed to determine the effect of varying
specific parameter inputs for each strategy. Details of all costs, model parameters, and model assump-
tions are provided in the supplemental text.
RESULTS
Of the 1,257 patients randomized to the LAM study arm, 561 patients were selected
for analysis based on availability of sputum culture results and Xpert results for analysis
(Fig. 1). The baseline patient characteristics are summarized in Table 1. The reference
standard for the diagnosis of TB in the primary analysis was a positive sputum culture,
which was reported for 31.7% of this cohort (178/561). Any positive TB-specific test
(Xpert, urine LAM test, or sputum culture) was used as a reference standard in
secondary analyses.
Test characteristics of single, sequential, and concurrent testing strategies
incorporating the LAM and Xpert tests in hospitalized patients irrespective of CD4
counts. The sensitivities, specificities, PPVs, and NPVs (95% confidence intervals [CIs]) of
the different strategies were as follows (Table 2): for Xpert only, 74.7% (67.7% to 80.9%),
95.1% (92.4% to 97.0%), 87.5% (81.2% to 92.3%), and 89.0% (85.6% to 91.9%), respec-
tively; for LAM testing only, 38.2% (30.9% to 45.7%), 88.3% (84.6% to 91.3%), 60.2%
(50.5% to 69.3%), and 75.5% (71.3% to 79.4%), respectively; and for sequential
(Xpert in LAM-negative patients and LAM in Xpert-negative patients) and concurrent
(LAMXpert) testing, 78.1% (71.3% to 83.9%), 85.1% (81.2% to 88.5%), 70.9% (65.5% to
75.8%) and 89.3% (86.3% to 91.7%), respectively. When the sequential/concurrent












Median age, yrs (95% CI) 36.0 (18–75) 37.3 (19–70) 37.6 (18–75) 36.8 (19–61) 0.31
No. of males:females (% male) 294:267 (52.4) 190:171 (52.6) 77:66 (53.8) 27:30 (47.3) 0.71
Country of origin, no. (%) 0.79
South Africa 151 70 (27.5) 74 (29.1) 7 (13.5)
Tanzania 193 96 (37.7) 97 (38.2) 0 (0.0)
Zambia 217 89 (34.9) 83 (32.7) 45 (86.5)
Median Karnofsky score (95% CI) 60 (20–90) 60.0 (20–90) 60.0 (30–90) 50.0 (50–60) 0.91
Median CD4 count, cells/mm3 (95% CI)
Total 99.5 (1–933) 58 (1–199) 320 (201–933) 0.0001
Patients with any positive TB result 73.0 (1–695) 44 (1–199) 283 (206–695) 0.0001
Median BMI (95% CI)b 18.7 (9–37) 18.6 (9–27) 19.4 (10–37) 17.1 (16.6–19.3) 0.002
No. of positive culture results/total (%) 178/561 (31.7) 127/361 (35.2) 35/143 (24.5) 16/57 (28.1) 0.02
aValue for the group with CD4 counts of 200 versus those with count of 200 cells/mm3. Boldface indicates statistical significance.
bBMI, body mass index.
TABLE 2 Diagnostic performance of sputum-based Xpert MTB/RIF and urine-based Alere Determine TB LAM Ag testing irrespective of
CD4 counta
Test strategy
% (95% CI) Likelihood ratio
Sensitivity Specificity PPV NPV Positive Negative
Xpert MTB/RIF only 74.7 (67.7–80.9) 95.1 (92.4–97.0) 87.5 (81.2–92.3) 89.0 (85.6–91.9) 15.1 (9.7–23.6) 0.27 (0.2–0.34)
Urine LAM test only 38.2 (31.0–45.7) 88.3 (84.6–91.3) 60.2 (50.5–69.3) 75.5 (71.3–79.4) 3.3 (2.3–4.5) 0.7 (0.6–0.8)
Sequential or concurrent testingb 78.1 (71.3–83.9) 85.1 (81.2–88.5) 70.9 (65.5–75.8) 89.3 (86.3–91.7) 5.3 (4.1–6.8) 0.3 (0.2–0.34)
aDiagnostic performance of sputum-based Xpert MTB/RIF and urine-based Alere Determine TB LAM Ag testing using single and sequential testing strategies in HIV-
infected hospitalized patients irrespective of CD4 count and using sputum culture positivity as the reference standard.
bSequential testing refers to performing Xpert for LAM-negative patients or LAM for Xpert-negative patients; concurrent testing refers to both tests being performed
at the same time rather than reflex testing based on the initial test result (in all 3 scenarios, the number of TB cases diagnosed remains the same, and hence,
sensitivities and specificities are identical).
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testing strategies were compared to Xpert only, there was a significant decrease in
specificity (10.0% difference [95% CI, 6.2% to 14.6%]; P  0.0001) and PPV (16.6%
difference [95% CI, 9.1% to 25.7%]; P  0.001). However, no difference in sensitivity
(3.4% difference [95% CI, 12.2% to 5.4%]; P  0.22) and NPV was observed (0.3%
difference [95% CI, 4.6% to 4.0%]; P  0.45).
Test characteristics of single and sequential/concurrent testing strategies in-
corporating LAM and Xpert testing in hospitalized patients with CD4 counts of
<50 and <200 cells/mm3. When test performance was assessed in patients with CD4
counts of 50 cells/mm3, the LAM test-only strategy showed improved sensitivity and
PPV (60.0% [47.1% to 72.0%] and 67.2% [53.7% to 79.0%], respectively) (Table 3) but a
slightly reduced specificity and NPV (81.7% [72.9% to 88.6%] and 77.0% [68.1% to
84.4%], respectively), compared to the entire cohort (not stratified by CD4 count). A
similar pattern was observed in the Xpert-only strategy, with a sensitivity, specificity,
PPV, and NPV of 81.5% (71.3% to 89.2%), 94.3% (88.1% to 97.9%), 89.2% (79.8% to
95.2%), and 89.9% (83.8% to 94.2%), respectively (Table 3). However, sequential/
concurrent testing did not show a significant difference in sensitivity compared to
Xpert only (89.2% [79.1% to 95.6%]; P  0.28) in this patient group. A similar pattern,
albeit to a lesser extent, was observed when patients with CD4 counts of 200 cells/
mm3 were analyzed (Table 3).
Incremental yield of urine LAM testing and Xpert in sequential testing strate-
gies. The incremental yield of urine LAM testing in the strategy of using the LAM test
in Xpert-negative patients was 4.5% (6 urine LAM-positive results/132 Xpert-positive
results) (Table 4), while the incremental yield of Xpert testing in the LAM-negative
strategy was 104% (71 Xpert-positive results/68 urine LAM-positive results). When the
analysis was repeated using any positive TB microbiological test (urine LAM test, Xpert,
or sputum culture) as a reference standard for the diagnosis of TB (as is the case in
clinical practice), the incremental yield of LAM in the strategy of using the LAM test in
Xpert-negative patients increased from 4.5% (with sputum culture as a reference) to
29.6% (Table 4). The incremental yield of Xpert or LAM testing, using any positive
microbiological test for TB as a reference standard, was also dependent on CD4 count
(Fig. 2).
Economic evaluation. The total costs of the sequential (LAM in Xpert-negative and
Xpert in LAM-negative patients) and concurrent (LAMXpert) testing strategies were
similar, ranging from $400,656 to $402,909 per 1,000 patients screened (Table 5). Costs
associated with unnecessary treatment were higher in the sequential and concurrent






Sensitivity Specificity PPV NPV
Sputum culture positivity 50 Xpert MTB/RIF only 81.5 (71.3–89.2) 94.3 (89.1–97.5) 89.2 (79.8–95.2) 89.9 (83.8–94.2)
Urine LAM test only 60.0 (47.1–72.0) 81.7 (72.9–88.6) 67.2 (53.7–79.0) 76.6 (67.6–84.1)
Sequential or concurrent testing 89.2 (79.1–95.6) 79.8 (70.8–87.0) 73.4 (62.3–82.7) 92.2 (84.6–96.8)
200 Xpert MTB/RIF Only 80.3 (72.3–86.8) 94.9 (91.3–97.3) 89.5 (82.3–94.4) 90.0 (85.5–92.4)
Urine LAM test only 44.9 (36.1–54.0) 88.1 (83.3–92.0) 67.1 (56.0–76.9) 74.8 (69.3–79.8)
Sequential or concurrent testing 83.5 (75.8–89.5) 84.7 (79.5–89.1) 74.6 (66.7–81.6) 90.5 (85.8–94.0)
Any microbiological test
positivityc
50 Xpert MTB/RIF only 71.3 (60.6–80.5) 77.1 (70.7–82.4)
Urine LAM test only 66.7 (55.8–76.4) 74.3 (68.3–79.6)
Sequential or concurrent testing 92.0 (84.1–96.7) 92.3 (85.5–96.1)
200 Xpert MTB/RIF only 69.9 (62.3–76.9) 80.3 (76.4–83.8)
Urine LAM test only 52.2 (44.1–60.0) 71.9 (68.6–75.1)
Sequential or concurrent testing 87.1 (81.0–91.8) 90.5 (86.5–93.4)
aDiagnostic performance of sputum-based Xpert MTB/RIF and urine-based Alere LAM in single, sequential, and concurrent testing strategies in HIV-infected
hospitalized patients with CD4 counts of 50 and 200 cells/mm3 using sputum culture or any microbiological test positivity as a reference.
bSequential testing refers to performing Xpert in LAM-negative patients or LAM in Xpert-negative patients; concurrent testing refers to performing both Xpert and
LAM concurrently.
cSpecificity and PPV could not be determined when any microbiological test positivity is used as a reference standard (as this will always equate to 100%).
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testing strategies ($186,228 to $187,235 per 1,000 patients screened), as more individ-
uals with false-positive test results were started on treatment. LAM testing only was the
cheapest strategy, followed by Xpert only ($305,927 and $355,358 per 1,000 patients
screened, respectively). The higher cost of sequential/concurrent testing was a conse-
quence of more individuals being correctly diagnosed and subsequently started on
treatment (248 patients in each strategy) compared to LAM only (121 patients) and
Xpert only (237 patients). However, sequential/concurrent testing also had the fewest
missed culture-positive TB cases (49 patients in each strategy) and empirically treated
patients (195 patients in each strategy; see Table S6 in the supplemental material). The
costs per culture-positive case diagnosed and started on treatment for the sequential
and concurrent testing strategies were very similar (costs for LAM in Xpert-negative
patients, Xpert in LAM-negative patients, and LAMXpert strategies were $1,617,
$1,621, and $1,625, respectively) but still slightly higher than for Xpert only ($1,500).
LAM testing only remained the least cost-effective strategy ($2,525) (Table 5).
A univariate sensitivity analysis indicated that TB prevalence, the rate of empirical
treatment, and TB treatment costs were the most influential parameters on cost-




% of patients diagnosed with
TB with the initial testb
Incremental diagnostic yield (%)
in patients who test negative
with the initial testc
Xpert followed by LAM in Xpert-
negative patients
TB culture 74.7 (133/178) 4.5 (6/133)
Any TB-positive test 64.7 (152/235) 29.6 (45/152)
LAM followed by Xpert in LAM-
negative patients
TB culture 38.2 (68/178) 104 (71/68)
Any TB-positive test 47.6 (112/235) 75 (84/112)
aAny positive test refers to a positive result obtained from MGIT sputum culture, Xpert MTB/RIF, or urine LAM testing. It is acknowledged that inclusion of Xpert or
LAM in the reference standard represents inclusion bias that tends to overestimate sensitivity (data are provided for purposes of comparison).
bNumbers in parentheses are number of positive patients/total.
cNumbers in parentheses are Xpert-positive results/LAM-positive results.
FIG 2 Incremental yield of LAM testing (LAM positivity in Xpert-negative patients) and Xpert (Xpert
positivity in LAM-negative patients) when any positive TB specific test was used as a reference standard
in patients with CD4 counts of 200 cells/mm3.
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effectiveness (Fig. S3). Subsequently, the cost per culture-positive patient diagnosed
and started on treatment for each strategy was plotted against increasing TB preva-
lence and empirical TB treatment rate, as these tend to vary widely in different settings.
The cost-effectiveness values decreased as prevalence increased, but the rankings
remained unchanged (Xpert alone was cheapest, followed by sequential/concurrent
strategies). However, the magnitude of the cost difference between the sequential/
concurrent testing strategies and Xpert only decreased (Fig. S4A). A similar reduction in
the cost difference between strategies was observed when empirical treatment rate
increased, until 70%, when the cost per outcome of the sequential/concurrent
strategies became less than that of Xpert alone (Fig. S4B). In both cases, the LAM-only
strategy was the least cost-effective.
DISCUSSION
We evaluated the benefit of using Xpert and urine LAM testing performed either
singly, sequentially, or concurrently in sputum-expectorating, hospitalized, HIV-infected
patients with suspected TB. Our key findings were as follows: (i) Xpert performs better
than the urine LAM test, irrespective of CD4 count; (ii) serial/concurrent testing using
Xpert and LAM (Xpert in LAM-negative patients, LAM in Xpert-negative patients, and
LAMXpert) improves sensitivity over either test alone; (iii) LAMXpert may be the
most appropriate strategy for diagnosing TB, especially in the setting of advanced
immunosuppression (CD4 count of 200 cells/mm3), since each of these tests inde-
pendently diagnoses patients with active TB, and moreover, the incremental yield of
LAM over Xpert increases with increasing immunosuppression; and (iv) the costs per TB
case diagnosed and started on treatment were similar for the sequential and concur-
rent strategies ($1,617 to $1,625) and only $120 more than the Xpert-only strategy.
There are few data about how to optimally use or combine different TB tests in a
clinical setting. A positive result with either Xpert or LAM is considered diagnostic for
TB and will prompt the clinician to treat for TB. Given this consideration, we analyzed
the data using 2 reference standards: (i) sputum culture positivity and (ii) any TB
microbiological test positivity. Using the former (Table 4), urine LAM provided a modest
incremental yield of 4.5% (6 patients) in Xpert-negative patients. In contrast, when
Xpert, sputum culture, or LAM positivity (i.e., any microbiological test positivity) was
used as a reference, the urine LAM test incremental yield was 30% in Xpert-negative
patients. This group (Xpert negative and LAM positive) had the lowest Karnofsky scores
and highest mortality in our cohort (Table S2). When only patients with CD4 counts
of 50 cells/l were included, LAM sensitivity improved by 20% and 26% when sputum
culture and any positive microbiological test were used as references, respectively. This
suggests that the patients with lower CD4 counts benefit most from LAM testing.
However, even in this group with advanced HIV, the overall sensitivity of Xpert was
superior to that of LAM (Table 3). Thus, our data support the need for a strategy
incorporating both tests, especially at lower CD4 counts (200 cells/mm3), given that
each test independently identifies patients with active TB (in this scenario, a patient’s
urine and sputum samples would be taken simultaneously and both tests would be run
concurrently).
Our findings are consistent with a Ugandan study in which a combination of LAM
and sputum Xpert testing had a greater sensitivity than either test alone (22). Impor-
tantly, the parent study (17) demonstrated a survival benefit with a LAM-guided testing
strategy due to more rapid treatment initiation. More recently, the STAMP trial, which
assessed patient outcomes using a concurrent LAM and Xpert diagnostic strategy,
demonstrated significantly reduced mortality (7.1%) in patients with CD4 counts of
100 cells/l and detected more TB cases compared to Xpert alone (21.9% versus
14.9%; P  0.001) (15). Thus, in sputum-expectorating patients, concurrent testing
leverages the advantages of both tests, i.e., LAM allows rapid treatment initiation while
Xpert results are awaited to ascertain resistance to rifampicin (Xpert results may take up
to 10 days in some settings where these diseases are endemic and has obvious
relevance in settings where rifampicin resistance is common) (23, 24); this strategy is
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also broadly cost neutral. However, there is also a reduction in specificity with sequen-
tial/concurrent testing, especially at low CD4 counts, that subsequently results in a
higher number of false positives. As such, the consequences of initiating treatment
unnecessarily must also be considered when a testing strategy is chosen, especially
when there is an increased risk of adverse drug reactions, such as those associated with
second-line TB treatment. Furthermore, in patients who are unable to expectorate
sputum, LAM testing is the obvious first choice, and our findings in this subgroup
(patients with scarce sputum) have been reported separately (25).
There are no cost-related data to inform test selection in settings where TB is
endemic. Our cost-consequence analysis indicated that the costs per culture-positive
patient diagnosed and started on treatment for the sequential/concurrent strategies
were similar ($1,617 to $1,626) and only marginally higher than that of using Xpert
alone ($1,500). The cost similarity is explained by the LAM assay having a low unit cost,
and it had little contribution to the overall strategy-specific costs. Treatment costs were
greater with sequential/concurrent testing because more culture-positive patients were
started on treatment than with the Xpert-only (11 more patients) and LAM test-only
(127 more patients) strategies. However, the additional cost of $120 for every TB
patient diagnosed and started on treatment when LAM testing is incorporated into
Xpert-based diagnostic strategies is likely justifiable, as hospitalized patients with
advanced HIV immunosuppression are at higher risk for misdiagnosis and poor out-
comes if treatment is not rapidly initiated (26). This is in agreement with other
cost-effectiveness studies evaluating the addition of LAM testing to existing TB diag-
nostic tests (27), including one related to the STAMP trial (28). Implementation costs of
these strategies would also likely be affordable given the relatively low LAM unit test
cost and lack of need for additional infrastructure or expertise. Furthermore, the
sequential/concurrent strategies were more cost-effective than Xpert only at high TB
prevalence and high empirical treatment rates, making this a particularly economically
attractive approach in such settings.
Our study has several limitations. We confined our analysis to patients who could
expectorate sputum, yet LAM may be most beneficial in those whose sputum is scarce
or who have EPTB. However, the main aim of our study was to inform diagnostic
algorithms in settings where other rapid sputum-based diagnostics, such as Xpert, were
available, and the findings in patients with scarce sputum were published elsewhere
(25). Furthermore, this was a post hoc analysis, utilizing a limited subset of the patients
recruited into the parent study, which may limit generalizability of the findings.
However, patients were recruited from 4 different countries in sub-Saharan Africa, and
this is the largest study to date comparing LAM test and Xpert incremental yields in
patients from whom sputum could be obtained. Third, the parent study was conducted
before the availability of Xpert Ultra, which is a more sensitive test (29), but it is unlikely
that this would have impacted our conclusions (Ultra overall has an 5% increased
sensitivity and a disadvantage of a higher false-positive rate in patients with a history
of TB) (29). It is possible that the LAM test may provide additional diagnostic value
when Xpert Ultra trace results in high-risk populations are interpreted (but not for
detection of rifampicin resistance, which cannot be inferred using a trace readout).
Finally, cost-effectiveness was calculated using clinical outcomes rather than single-
utility metrics such as disability-adjusted life years (DALYs), so we cannot explicitly state
that these strategies are cost-effective compared to Xpert only in the traditional sense,
i.e., below the classical willingness-to-pay threshold of three times the per-capita GDP
per DALY averted. Furthermore, we did not incorporate other clinical outcomes, such
as death or additional TB cases missed due to insufficient data. Given the high mortality
risk in this population, it is likely that inclusion of these effects would, if anything, have
improved the cost-effectiveness of the sequential/concurrent strategies.
Conclusion. In sputum-expectorating hospitalized patients with advanced HIV and
access to both tests, concurrent testing with Xpert and LAM is the most appropriate
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strategy for diagnosing TB. These data inform clinical practice in settings where TB and
HIV are endemic.
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